CN107502608A - Construction method and application for sgRNA, ALDH2 gene delection cell line for knocking out people's ALDH2 genes - Google Patents

Construction method and application for sgRNA, ALDH2 gene delection cell line for knocking out people's ALDH2 genes Download PDF

Info

Publication number
CN107502608A
CN107502608A CN201710803984.0A CN201710803984A CN107502608A CN 107502608 A CN107502608 A CN 107502608A CN 201710803984 A CN201710803984 A CN 201710803984A CN 107502608 A CN107502608 A CN 107502608A
Authority
CN
China
Prior art keywords
aldh2
sgrna
genes
cell
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201710803984.0A
Other languages
Chinese (zh)
Other versions
CN107502608B (en
Inventor
王庆
王飞
郭涛
李若碧
汪红梅
王婷
曾妮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Yat Sen University
National Sun Yat Sen University
Original Assignee
National Sun Yat Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Sun Yat Sen University filed Critical National Sun Yat Sen University
Priority to CN201710803984.0A priority Critical patent/CN107502608B/en
Publication of CN107502608A publication Critical patent/CN107502608A/en
Application granted granted Critical
Publication of CN107502608B publication Critical patent/CN107502608B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/10Applications; Uses in screening processes
    • C12N2320/11Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

The invention provides a kind of sgRNA sequences for being used to knock out people's ALDH2 genes, the target DNA sequence of the sgRNA is SEQ ID NO:1、SEQ ID NO:2、SEQ ID NO:At least one in sequence shown in 3.Present invention also offers a kind of method for knocking out human liver cancer cell ALDH2 genes, to be transformed using CRISPR/Cas systems in human liver cancer cell ALDH2 genes.Present invention also offers two kinds of ALDH2 gene delection cell line cell lines, ALDH2 participates in the important metabolic function of body, metabolism research of the ALDH2 Knockout cells strain provided by the invention for exogenous chemical or exogenous poisonous substance in vivo provides effective platform, and powerful is provided for chronic disease (such as alcoholic Jiver disease and diabetes) and the research of tumor-related illness.

Description

For the structure for sgRNA, ALDH2 the gene delection cell line for knocking out people's ALDH2 genes Method and application
Technical field
The present invention relates to genetic engineering field, and in particular to it is a kind of be used for knock out people's ALDH2 genes gRNA sequences, The construction method of ALDH2 gene delection cell lines and its application.
Background technology
ALDH2 is the very important hypotype of acetaldehyde dehydrogenase, on No. 12 chromosome of human body (12q24.2), Main function is into acetic acid by oxidation of acetaldehyde, and it participates in the metabolism in vivo of the secondary metabolite acetaldehyde of alcohol and detoxified Journey, promote alcohol to be metabolized in liver, be considered as having close associate with Asian alcohol metabolism and alcohol dependence.
Slow virus system is that current mediation aim sequence enters one of method of target cell, is developed based on HIV A kind of method come, it overcomes the defects of fractionated viral system can only infect division cells, and slow virus system can both be felt Dye division stage, can infect nondividing phase cell again, and target gene can be integrated into host cell gene group, and it is lasting to play And stable disturbing effect.
The principle that limiting dilution assay selects monoclonal cell is to utilize gradient dilution, can be with when dilution gradient is sufficiently high The single cell of acquisition, culture can obtain the single cell line of background after breeding.Limiting dilution assay it is simple to operate, it is easy To monoclonal cell strain.
CRISPR/Cas9 systems are a kind of acquired immunity systems of defense, to protect bacterium or archeobacteria from external matter The CRISPR sequences of grain or the intrusion of bacteriophage, this kind of bacterium or archeobacteria genome can be expressed and invader's genome sequence phase The RNA of identification, foreign gene group DNA is cut in the presence of CRISPR relevant enzymes (CAS9), reach the purpose for resisting invasion, warp After crossing artificial reforming, CRISPR/Cas9 systems can realize high flexible and special genome editor in eukaryotic, be The most popular genome editing technique of new generation in genome editor field at present, at present the technology have been used for building all kinds of bases Because knocking out cell line and Gene Knock-Out Animal Model model.
In existing experimental technique, the gene silent technology with CRISPR/Cas9 systems the most similarly siRNA targetings SiRNA refers to the gene silencing phenomenon that the double-stranded RNA that biology is highly conserved during evolution induces, and it influences the system of organism one Row process and function, but under the inducing action of medicine etc., the phenomenon that expression is replied occurs in the gene being silenced.With siRNA Targeting ALDH2mRNA inhibition of gene expression is compared, and CRISPR/Cas9 carries out gene editing in ALDH2 genomic levels, can be with complete The expression of full cryptiogene, builds real ALDH2 gene defection types cell line.
At present, it is necessary to provide it is a kind of can not only realize silence thoroughly and can in vitro culture steady in a long-term ALDH2 genes Defect type human hepatoma cell strain.
The content of the invention
To solve the above problems, the invention provides for knocking out the sgRNA sequences of people's ALDH2 genes, ALDH2 genes lack Lose construction method and its application of cell line.
In a first aspect, the invention provides a kind of sgRNA sequences for being used to knock out people's ALDH2 genes, the target of the sgRNA DNA sequence dna is SEQ ID NO:1、SEQ ID NO:2、SEQ ID NO:At least one in sequence shown in 3.
Second aspect, the invention provides a kind of method for knocking out Human embryo kidney cell ALDH2 genes, to utilize CRISPR/Cas systems are transformed ALDH2 genes in human liver cancer cell, are specifically comprised the following steps:
(1) artificial synthesized target DNA sequence as described in relation to the first aspect and its complementary strand;
(2) synthesized nucleic acid fragment is inserted into multiple cloning sites and conversion of the sgRNA Skeleton Tables up to plasmid vector, chosen Monoclonal bacterial strain, sgRNA recombinant plasmids are extracted, sequencing identification, which obtains, is sequenced correct sgRNA recombinant plasmids;Wherein, sgRNA bones Frame expression plasmid carrier also expresses Cas9 nucleases;
(3) by sgRNA Transfected Recombinant Plasmid human liver cancer cells, the Human embryo kidney cell for knocking out ALDH2 genes is produced.
Preferably, the step (2) specifically includes:By synthesized SEQ ID NO:1、SEQ ID NO:2 and SEQ ID NO:The nucleic acid of sequence shown in 3 chooses Dan Ke to being inserted respectively into multiple cloning sites and conversion of the sgRNA Skeleton Tables up to plasmid vector Grand bacterial strain, sgRNA recombinant plasmids are extracted, sequencing identification, which obtains, is sequenced correct sgRNA recombinant plasmids;Wherein, sgRNA Skeleton Tables Cas9 nucleases are also expressed up to plasmid vector;
The step (3) specifically includes:By two kinds of sgRNA recombinant plasmid cotransfection human liver cancer cells obtained by step (2), Produce the human liver cancer cell for knocking out ALDH2 genes.
The third aspect, the invention provides the construction method of two kinds of ALDH2 gene delection cell lines, respectively using slow disease Malicious infection protocol, limiting dilution assay carry out passage screening to the human liver cancer cell of the knockout ALDH2 genes obtained by second aspect, obtain The stable human liver cancer cell for knocking out ALDH2 genes.
Fourth aspect, the invention provides two kinds of ALDH2 gene delection cell lines, are using as described in the third aspect Obtained by the construction method of ALDH2 gene delection cell lines.
5th aspect, the invention provides a kind of sgRNA sequences for being used to knock out people's ALDH2 genes as described in relation to the first aspect It is listed in the application knocked out in ALDH2 genes.
6th aspect, one kind are used to carrying out that ALDH2 is gene site-directed to knock in kit in human genome, including following (1)- Any of (3):
(1) the sgRNA sequences for being used to knock out people's ALDH2 genes as described in relation to the first aspect;
(2) the sgRNA recombinant plasmids as described in second aspect;
(3) the ALDH2 gene delection cell lines as described in fourth aspect.
The invention provides technical scheme have the advantages that:
Technical scheme provided by the invention, to ALDH2 gene knockouts, is realized in genome using CRISPR/Cas9 technologies The horizontal silence to gene acts on, and it is not thorough or can not silence in the silence of mRNA or protein level to effectively improve siRNA The shortcomings that gene expression.
Brief description of the drawings
Fig. 1 is experimental design process figure provided in an embodiment of the present invention;
Fig. 2 is SgRNA construction of recombinant plasmid ideograph provided in an embodiment of the present invention;
Fig. 3 is that monoclonal cell limiting dilution assay provided in an embodiment of the present invention screens HepG2 knockout cell line sequencing knots Fruit;
Fig. 4 is PCR fragment result after SURVEYOR nuclease digestions provided in an embodiment of the present invention;
Fig. 5 is the stable strain T-A cloning and sequencing results of HepG2 of ALDH2 gene knockouts provided in an embodiment of the present invention;
Fig. 6 is the HepG2 cell line mrna expression amount testing results of ALDH2 gene knockouts provided in an embodiment of the present invention;
Fig. 7 is the HepG2 cell line Protein expression quantity detection knot of ALDH2 gene knockouts provided in an embodiment of the present invention Fruit.
Embodiment
As described below is the preferred embodiment of the present invention, it is noted that for those skilled in the art For, under the premise without departing from the principles of the invention, some improvements and modifications can also be made, these improvements and modifications are also considered as Protection scope of the present invention.
Outer without special instruction in the embodiment of the present invention, agents useful for same and consumptive material are commercial goods.
Experimental design process figure shown in technical solution of the present invention combination Fig. 1, is realized by following examples:
(1) sgRNA is designed:
Respectively for the second, the 4th and the 5th extron (Exon2, Exon4, Exon5) the design sgRNA of ALDH2 genes Sequence.
Design, three component safety pins of synthesis are specific to the sgRNA sequences of ALDH2 genes the second, the 4th and the 5th extron Packet is shown in Table 1 with name:
The ALDH2sgRNA oligo sequences of table 1
(Tab.1 The sequences of ALDH2sgRNA oligo)
Respectively in the enzyme-added enzyme site in sgRNA both ends, CACC, antisense are added at 5 ' ends of the positive-sense strand of every sgRNA sequence 5 ' end addition AAAC of chain, so as to form the cohesive end complementary after Fast Digest Bbs I digestions with PX461 plasmids. If 5 ' first base in end of positive-sense strand are not G, increase a G behind 5 ' end CACC, the corresponding end of antisense strand 3 ' is again Increase a C.SgRNA after the completion of design serves Hai Jierui companies and carries out primer synthesis.
SEQ ID NO of the present invention:1、SEQ ID NO:2、SEQ ID NO:Sequence shown in 3 corresponds to SEQ in form 1 respectively ID NO:4、SEQ ID NO:6、SEQ ID NO:8 draw horizontal line part, specifically, SEQ ID NO:1、SEQ ID NO:2、SEQ ID NO:Sequence is respectively shown in 3CCAGTGGACGGATTGACGGTCATAGGGCTTGCCATTGTCCCTGAAGAAGTCTCCGTCAAT
(2) structure of recombinant plasmid and identification, structure process mode are as shown in Figure 2
1. PX458 and Lenticrispr V2 are the sgRNA skeleton expression vectors containing U6 promoters, expression has The Cas9n of Cas9D10A otch enzyme mutants, PX458 plasmids carry GFP green fluorescence protein genes and amicillin resistance, Lenticrispr V2 plasmids carry amicillin resistance.With Fast Digest Bbs I to PX458 and Lenticrispr V2 carries out digestion, and the carrier of linearisation is reclaimed after DNA gel electrophoresis.
2. phosphorylation and annealing are carried out to three groups of sgRNA oligo sequences in table 1 respectively with T4PNK;Use T4ligase By linear linear PX458 and Lenticrispr V2 plasmid vectors respectively with three groups of sgRNA double-stranded sequences rooms after annealing Temperature connection 1h.Connection product transformed competence colibacillus bacterium Trans 109, ice bath 30min, 42 DEG C of 45s, on ice 2min.Resist in ammonia benzyl Screening and cloning on the LB flat boards of property.Picking positive colony shakes bacterium, send sequencing.Sequencing primer is the forward primer sequence of U6 promoters Row, 5 '-GAGGGCCTATTTCCCATGATTCC-3 ' (SEQ ID NO:15).Correctly clone extracts recombinant plasmid for sequencing.
3. gained recombinant plasmid shares six groups, for recombinant plasmid obtained by PX458 plasmids be named as PX458-Exon2, PX458-Exon4 and PX458-Exon5, the recombinant plasmid obtained by Lenticrispr V2 plasmids are named as Lenticrispr V2-Exon2, Lenticrispr V2-Exon4 and Lenticrispr V2-Exon5.
(3) slow virus system virus liquid structure HepG2 stable cell lines
1. the generation of virus
293FT cell culture conditions:DMEM culture mediums (containing 10% hyclone), 5%CO2, 37 DEG C it is incubated.
293FT cells are inoculated with 10cm Tissue Culture Dish respectively, cell inoculation number is 2 × 106, according to core plasmid: Packaging plasmid:Envelope plasmid=4:3:2 ratio is transfected, and sgRNA group core plasmids are respectively Lenticrispr V2- Exon2, Lenticrispr V2-Exon4 and Lenticrispr V2-Exon5, with Lenticrispr v2 as a control group. 24h after transfection, 48h and 72h are received and virus liquid, and fluorecyte percentage is observed using inverted fluorescence microscope, it is determined that transfection Efficiency.The virus liquid three times of collection is mixed, the virus liquid of collection concentrated using Milipore 100KD evaporating columns.Profit Virus liquid titer determination is carried out with 293FT cells.
2. cell infection and the stable strain cell screenings of HepG2.
HepG2 cell culture conditions be DMEM culture mediums (containing 10% hyclone), 5%CO2,37 DEG C it is incubated.
Propose the aim cell strain to be infected well of the previous day kind in 6 orifice plates, cell infection is that cell collects rate and reaches 40-50% It is advisable.Culture medium is sucked before infection, 120 μ l viral concentration liquid is diluted with 2ml fresh cultures, 3.5g polybrenes is added, in sense 48~96h observes efficiency of infection under inverted fluorescence microscope after dye.96h is mould using final concentration of 2 μ g/ml purine after infection Element is screened, and screening time is 7 days.Maintained after puromycin screens with final concentration of 0.5 μ g/ml puromycin HepG2 stable cell lines.
(4) monoclonal cell limiting dilution assay screening HepG2 knocks out cell line
1. cell transfecting:24h before transfection, HepG2 cells are seeded in 6 orifice plates with 5 × 105/ holes and cultivated, it is thin during transfection Born of the same parents' degrees of fusion reaches 60%-70%.Using Viafect transfection reagents respectively by PX458-Exon2, PX458-Exon4 and PX458-Exon5 transfects a hole HepG2 cells simultaneously, and the PX458 plasmids of equivalent are as negative control, 6 orifice plate plasmid transfection amounts The ratio between generally 2ug/ holes, the pre- transfection reagent of plasmid are 1:2-2.5.Transfection efficiency is observed after 24h.Utilize inverted fluorescence microscope Fluorecyte percentage is observed, to determine transfection efficiency.
2. monoclonal cell limiting dilution assay screens monoclonal cell:With trypsin digestion and cell and count, using having Limit dilution method is diluted to 0.5 cell of 100ul culture mediums, is added to by every hole 100ul cell diluents in 96 orifice plates.After inoculation Go out monoclonal cell with micro- sem observation cell growth condition and preliminary screening within 5 to 7 days, when cell covers with 96 orifice plate bottom, then With trypsin digestion and cell and it is transferred in 24 orifice plates.When cell covers with 24 orifice plate bottom, a part of cell stays for passage Kind, its genomic DNA of a part of cell extraction, it is sequenced after PCR is expanded, sequencing result is compared with protogene group, detection Whether targeting knock out ALDH2 genes succeed.
Sequencing result, wild type is compared, HepG2 knocks out cell line there occurs the missing of one section of 4bp base, as shown in Figure 3.
(5) cell genomic dna is extracted
Constructed cell line is digested, uses GeneJETTMGenomic DNA Purification Kit are extracted Genomic DNA.
1. cell is collected in centrifuge tube, often pipe 5X106Individual cell, slowly blown and beaten, 250g centrifugation 5min, abandoned with pipettor Supernatant, add PBS that cell is resuspended, repeated centrifugation, has removed remaining medium in cell again.
2. cell is resuspended with 200ul PBS, often pipe adds 200ul lysates and 20ul Proteinase Ks, fully shaking, mixing Uniformly.
3. 56 DEG C of shaking tables are incubated 10min, mixing is during which shaken per 3-4 minutes once, to ensure that cell cracking is abundant.
4. adding 20ul RNAase A, concussion mixes, and is incubated at room temperature 10min.
5. adding 400ul 50%ethanol, shaken with rifle and mix or shake mixing.
6. in the Column posts that above-mentioned MiX addition kits are provided, 6000g centrifugations, 1min, DNA is collected into post transfer Into new 2ml collecting pipes.
7. adding 500ul wash buffer I, 8000g centrifugation 1min, waste liquid is abandoned.Add 500ul wash buffer II, 12000g, centrifuge 3min.
8. it is central to post filter membrane is collected to add 200ul Elution Buffer, incubation at room temperature 2min, 8000g centrifugation, 1min, you can DNA sample needed for obtaining.
(6) PCR reaction conditions and SURVEYOR analysis detections
1. the ALDH2 gene mRNA sequences number provided according to NCBI design QRT-PCR primers;Designed by Primer 3.0 The SURVEYOR primers and PCR primer of ALDH2 genes, primer are synthesized by Shanghai JaRa biotech firm.
The SURVEYOR PCR of table 2 react primer sequence
Tab.2 PCR primer
Expanded 2. surpassing fidelity dna polymerase with Phusion and entering performing PCR, with reference to specification 50ul systems, genomic DNA 100ng, 50ul reaction system are as shown in the table.
Component Quantity (uL)
H2O to 50
Phusion HF buffer,5X 10
dNTPs,2.5mM 4
Phusion polymerase 0.5
Forward primer 2.5
Reverse primer 2.5
template DNA 100ng
Total 50
Program is as follows:
Negate should after PCR primer 5ul enter row agarose gel electrophoresis detect its specificity.
SURVEYOR analytical procedures are as follows:
1) carry out PCR primer with QIAquick PCR purification Kit kits to purify, recovery product is diluted To 40ng/ul, detection is carried out according to SURVEYOR assay kit specification steps
2) DNA heteroduplexs form (annealing reaction) system:
Component Quantity (μ l)
Taq PCR buffer,10× 2
Normalized PCR product,20ngμl-1 18
Total volume 20
Reaction condition:
Cycle-index Condition
1 95℃,10min
2 95-85℃,-2℃s-1
3 85℃,1min
4 85-75℃,-0.3℃s-1
5 75℃,1min
6 75-65℃,-0.3℃s-1
7 65℃,1min
8 65-55℃,-0.3℃s-1
9 55℃,1min
10 55-45℃,-0.3℃s-1
11 45℃,1min
12 45-35℃,-0.3℃s-1
13 35℃,1min
14 35-25℃,-0.3℃s-1
15 25℃,1min
16 25-4℃,-0.3℃s-1
17 4℃,hold
3) SURVEYOR nuclease digestions (being operated on ice):
Reaction system:
Component Dosage (μ l) Final concentration
Annealed heteroduplex 20
MgCl2stock solution supplied with kit,0.15M 2.5 15mM
ddH2O 0.5
SURVEYOR nuclease S 1
SURVEYOR enhancer S 1
Total 25
Reaction condition:Fully shaking, mix above-mentioned mixture, 42 DEG C of 30min.
4) 10ul samples are taken, are analyzed with 2% Ago-Gel.Cutting efficiency, formula are calculated with quantitative gel software For fcut=(b+c)/(a+b+c), wherein Indel are miss ratio, fcutFor cutting ratio Rate, a are the gray value for not being cut band, and b and c represent the gray value of new band caused by cutting.
The 293FT cells of that group transfection of selection Indel (%) highest do the inoculation and screening of next step.
SURVEYOR nuclease digestions partial results as shown in figure 4, test result indicates that
1) limiting dilution assay HepG2 knocks out strain
PX458-Exon2, PX458-Exon4 and the PX458- built for the sgRNA of Exon2, Exon4, Exon5 design Exon5 plasmid groups are effective, and SURVEYOR results are the positive.
2) slow-virus transfection method HepG2 knocks out strain
PX458-Exon2 the and PX458-Exon5 plasmids group built for the sgRNA of Exon2, Exon5 design is effective, SURVEYOR results are the positive.
(7) the HepG2 cell lines DNA sequencing analysis of ALDH2 gene knockouts
1. extracting cell genomic dna, enter performing PCR using Phusion high-fidelity enzymes, and PCR primer is purified, make Add A tails to above-mentioned PCR primer with Taq archaeal dna polymerases, reaction total system is 50 μ l, react specific needed for each component usage amount and Reaction condition is as follows:
2. connect carrier T:Above-mentioned plus A tails PCR primer is attached with carrier T, while using carrier T kit certainly The control setting negative control of band, each group component for reacting required are as follows:
Control group is as follows:
Often pipe adds Solution I (including the enzyme needed for coupled reaction) 5 μ l in above-mentioned reaction system, in 16 DEG C of connections 30min, entirely react and carried out in PCR instrument.
3. connection product transformed competence colibacillus bacterium Trans 109, ice bath 30min, 42 DEG C of 45s, on ice 2min.Resist in ammonia benzyl Screening and cloning on the LB flat boards of property.Picking positive colony shakes bacterium, send Beijing six directions Huada gene company sequencing.
As a result as shown in figure 5, the deletion mutation that the stable strains of HepG2 cause in target position, realizes ALDH2 clpp genes Remove.
(8) the HepG2 cell lines mRNA of ALDH2 gene knockouts and expressing quantity detection
1. using Trizol methods extraction cell total rna, reverse transcription, generation are carried out using TOYOBO companies Reverse Transcriptase kit CDNA, the system provided according to TOYOBO companies SYBR mix reagent specifications carry out qRT-PCR.
As a result as shown in fig. 6, successfully build ALDH2 gene knockouts HepG2 cell lines mrna expression amount significantly lower than pair According to group.
2. using M-PER cell pyrolysis liquids extraction HepG2ALDH2 Knockout cells strain total proteins, determined using BCA albumen Amount kit is quantified, and carries out Western Blot.
As a result as shown in fig. 7, successfully build ALDH2 gene knockouts HepG2 cell lines expressing quantity significantly lower than pair According to group.
Relative to traditional gene knockout method, not only flow is cumbersome, high to technical requirements, and somewhat expensive, success rate It is relatively low.The CRISPR-Cas9 technologies that the present invention uses are forth generation gene editing methods, and its is easily operated, more efficient, It is low-cost.The present invention is related for ALDH2 metabolism using the ALDH2 Knockout cells model of CRISPR-Cas9 technique constructions Research provide active platform.Specifically have the beneficial effect that:
(1) silence to gene in genomic level is realized to ALDH2 gene knockouts using CRISPR/Cas9 technologies Effect, effectively improve siRNA the silence of mRNA or protein level it is not thorough or can not cryptiogene expression the shortcomings that.
(2) ALDH2 participates in the important metabolic function of body, and what ALDH2 genes knocked out cell line is established as exogenous chemical The metabolism research of thing or exogenous poisonous substance in vivo provides effective platform.
(3) strain of ALDH2 Knockout cells is for chronic disease (such as alcoholic Jiver disease and diabetes) and tumour phase The research of related disorders provides powerful.
(4) ALDH2 Knockout cells strain can be used for that ALDH2 is metabolized related xenobiotic toxicity, carcinogenicity is ground Study carefully and medicine between reciprocation research.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all essences in the present invention All any modification, equivalent and improvement made within refreshing and principle etc., should be included in the scope of the protection.
Sequence table
<110>Zhongshan University
<120>Construction method and application for sgRNA, ALDH2 gene delection cell line for knocking out people's ALDH2 genes
<160> 21
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 1
ccagtggacg gattgacggt 20
<210> 2
<211> 20
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 2
catagggctt gccattgtcc 20
<210> 3
<211> 20
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 3
ctgaagaagt ctccgtcaat 20
<210> 4
<211> 25
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 4
caccgccagt ggacggattg acggt 25
<210> 5
<211> 25
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 5
aaacaccgtc aatccgtcca ctggc 25
<210> 6
<211> 25
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 6
caccgcatag ggcttgccat tgtcc 25
<210> 7
<211> 25
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 7
aaacggacaa tggcaagccc tatgc 25
<210> 8
<211> 25
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 8
caccgctgaa gaagtctccg tcaat 25
<210> 9
<211> 25
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 9
aaacattgac ggagacttct tcagc 25
<210> 10
<211> 23
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 10
cctgtgcttt tcatttgtag gct 23
<210> 11
<211> 23
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 11
cagtttcgat tggttcctac agt 23
<210> 12
<211> 20
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 12
tcctcctccc tgcctttgga 20
<210> 13
<211> 23
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 13
gccttctctg actcctgtga tcc 23
<210> 14
<211> 21
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 14
acaagaaccc caggcgattc t 21
<210> 15
<211> 22
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 15
tgcgtgtcct cccctaactc ca 22
<210> 16
<211> 19
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 16
ttgtctgcaa ggcctgtgc 19
<210> 17
<211> 22
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 17
ttggttccta cagtctgtac aa 22
<210> 18
<211> 20
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 18
tttacaagaa ccccaggcga 20
<210> 19
<211> 20
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 19
gaattcacga gtggcagtgc 20
<210> 20
<211> 20
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 20
cttagcatgg tgtcacggac 20
<210> 21
<211> 18
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 21
tgggattgca ggcgtgag 18

Claims (6)

1. a kind of sgRNA sequences for being used to knock out people's ALDH2 genes, it is characterised in that the target DNA sequence of the sgRNA is SEQ ID NO:1、SEQ ID NO:2、SEQ ID NO:At least one in sequence shown in 3.
A kind of 2. method for knocking out human liver cancer cell ALDH2 genes, it is characterised in that be in people liver using CRISPR/Cas systems ALDH2 genes are transformed in cancer cell, specifically comprised the following steps:
(1) artificial synthesized target DNA sequence as claimed in claim 1 and its complementary strand;
(2) synthesized nucleic acid fragment is inserted into multiple cloning sites and conversion of the sgRNA Skeleton Tables up to plasmid vector, chooses Dan Ke Grand bacterial strain, sgRNA recombinant plasmids are extracted, sequencing identification, which obtains, is sequenced correct sgRNA recombinant plasmids;Wherein, sgRNA Skeleton Tables Cas9 nucleases are also expressed up to plasmid vector;
(3) by sgRNA Transfected Recombinant Plasmid human liver cancer cells, the human liver cancer cell for knocking out ALDH2 genes is produced.
3. the construction method of two kinds of ALDH2 gene delection cell line cell lines, it is characterised in that respectively using slow-virus transfection Method, limiting dilution assay carry out passage screening to the human liver cancer cell of the knockout ALDH2 genes obtained by such as claim 2, obtain steady Surely ALDH2 human liver cancer cell is knocked out.
4. two kinds of ALDH2 gene delection cell line cell lines, it is characterised in that be as using as claimed in claim 3 Obtained by the construction method of ALDH2 gene delection cell lines.
5. a kind of sgRNA sequences as claimed in claim 1 for being used to knock out people's ALDH2 genes are in ALDH2 genes are knocked out Using.
6. one kind in human genome for carrying out, ALDH2 is gene site-directed to knock in kit, it is characterised in that including following (1)- Any of (3):
(1) the sgRNA sequences as claimed in claim 1 for being used to knock out people's ALDH2 genes;
(2) sgRNA recombinant plasmids as claimed in claim 2;
(3) ALDH2 gene delection cell lines as claimed in claim 4.
CN201710803984.0A 2017-09-08 2017-09-08 Construction method and application of sgRNA and ALDH2 gene-deleted cell strain for knocking out human ALDH2 gene Active CN107502608B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710803984.0A CN107502608B (en) 2017-09-08 2017-09-08 Construction method and application of sgRNA and ALDH2 gene-deleted cell strain for knocking out human ALDH2 gene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710803984.0A CN107502608B (en) 2017-09-08 2017-09-08 Construction method and application of sgRNA and ALDH2 gene-deleted cell strain for knocking out human ALDH2 gene

Publications (2)

Publication Number Publication Date
CN107502608A true CN107502608A (en) 2017-12-22
CN107502608B CN107502608B (en) 2020-10-16

Family

ID=60695284

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710803984.0A Active CN107502608B (en) 2017-09-08 2017-09-08 Construction method and application of sgRNA and ALDH2 gene-deleted cell strain for knocking out human ALDH2 gene

Country Status (1)

Country Link
CN (1) CN107502608B (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108277223A (en) * 2018-01-30 2018-07-13 中国人民解放军南京军区疾病预防控制中心 The structure of sgRNA, SOSSB1 gene delection cell strain for knocking out people's SOSSB1 genes and application
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10465176B2 (en) 2013-12-12 2019-11-05 President And Fellows Of Harvard College Cas variants for gene editing
US10508298B2 (en) 2013-08-09 2019-12-17 President And Fellows Of Harvard College Methods for identifying a target site of a CAS9 nuclease
WO2019237373A1 (en) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 Method for constructing 293t cell strain with site-directed insertion of btdc gene and use thereof
US10597679B2 (en) 2013-09-06 2020-03-24 President And Fellows Of Harvard College Switchable Cas9 nucleases and uses thereof
CN111254164A (en) * 2018-11-30 2020-06-09 中国科学院大连化学物理研究所 Method for rapidly establishing CRISPR gene editing liver cancer cell strain and cell strain
US10682410B2 (en) 2013-09-06 2020-06-16 President And Fellows Of Harvard College Delivery system for functional nucleases
US10704062B2 (en) 2014-07-30 2020-07-07 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US10858639B2 (en) 2013-09-06 2020-12-08 President And Fellows Of Harvard College CAS9 variants and uses thereof
US11046948B2 (en) 2013-08-22 2021-06-29 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US11214780B2 (en) 2015-10-23 2022-01-04 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US11932884B2 (en) 2022-03-21 2024-03-19 President And Fellows Of Harvard College High efficiency base editors comprising Gam

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106434752A (en) * 2016-06-14 2017-02-22 南通大学附属医院 Process of knocking out Wnt3a gene and verification method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106434752A (en) * 2016-06-14 2017-02-22 南通大学附属医院 Process of knocking out Wnt3a gene and verification method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FEI WANG ET AL.: "A comparison of CRISPR/Cas9 and siRNA-mediated ALDH2 gene silencing in human cell lines", 《 MOLECULAR GENETICS AND GENOMICS》 *
郭涛 等: "利用CRISPR/Cas9系统构建ALDH2基因敲除的HepG2细胞株", 《2017(第三届)毒性测试替代方法与转化毒理学(国际)学术研讨会会议论文集》 *

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US11920181B2 (en) 2013-08-09 2024-03-05 President And Fellows Of Harvard College Nuclease profiling system
US10954548B2 (en) 2013-08-09 2021-03-23 President And Fellows Of Harvard College Nuclease profiling system
US10508298B2 (en) 2013-08-09 2019-12-17 President And Fellows Of Harvard College Methods for identifying a target site of a CAS9 nuclease
US11046948B2 (en) 2013-08-22 2021-06-29 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US11299755B2 (en) 2013-09-06 2022-04-12 President And Fellows Of Harvard College Switchable CAS9 nucleases and uses thereof
US10597679B2 (en) 2013-09-06 2020-03-24 President And Fellows Of Harvard College Switchable Cas9 nucleases and uses thereof
US10912833B2 (en) 2013-09-06 2021-02-09 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US10682410B2 (en) 2013-09-06 2020-06-16 President And Fellows Of Harvard College Delivery system for functional nucleases
US10858639B2 (en) 2013-09-06 2020-12-08 President And Fellows Of Harvard College CAS9 variants and uses thereof
US10465176B2 (en) 2013-12-12 2019-11-05 President And Fellows Of Harvard College Cas variants for gene editing
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
US11124782B2 (en) 2013-12-12 2021-09-21 President And Fellows Of Harvard College Cas variants for gene editing
US11578343B2 (en) 2014-07-30 2023-02-14 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10704062B2 (en) 2014-07-30 2020-07-07 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US11214780B2 (en) 2015-10-23 2022-01-04 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US11702651B2 (en) 2016-08-03 2023-07-18 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10947530B2 (en) 2016-08-03 2021-03-16 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US11820969B2 (en) 2016-12-23 2023-11-21 President And Fellows Of Harvard College Editing of CCR2 receptor gene to protect against HIV infection
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
CN108277223A (en) * 2018-01-30 2018-07-13 中国人民解放军南京军区疾病预防控制中心 The structure of sgRNA, SOSSB1 gene delection cell strain for knocking out people's SOSSB1 genes and application
WO2019237373A1 (en) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 Method for constructing 293t cell strain with site-directed insertion of btdc gene and use thereof
CN111254164A (en) * 2018-11-30 2020-06-09 中国科学院大连化学物理研究所 Method for rapidly establishing CRISPR gene editing liver cancer cell strain and cell strain
US11643652B2 (en) 2019-03-19 2023-05-09 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11795452B2 (en) 2019-03-19 2023-10-24 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US11932884B2 (en) 2022-03-21 2024-03-19 President And Fellows Of Harvard College High efficiency base editors comprising Gam

Also Published As

Publication number Publication date
CN107502608B (en) 2020-10-16

Similar Documents

Publication Publication Date Title
CN107502608A (en) Construction method and application for sgRNA, ALDH2 gene delection cell line for knocking out people&#39;s ALDH2 genes
CN106191057B (en) A kind of sgRNA sequence for knocking out people&#39;s CYP2E1 gene, the construction method of CYP2E1 gene deleted cell strains and its application
CN105647969B (en) Method for breeding zebra fish with stat1a gene deletion by gene knockout
CN107012174A (en) Application of the CRISPR/Cas9 technologies in silkworm zinc finger protein gene mutant is obtained
CN106906242A (en) A kind of method that raising CRIPSR/Cas9 targeting knock outs gene produces nonhomologous end joint efficiency
CN109207515A (en) A method of design and building pig full-length genome CRISPR/Cas9 knock out library
CN112080521B (en) Recombinant pseudorabies virus vector construction for expressing foreign protein and preparation method of recombinant pseudorabies virus
EP3816296A1 (en) Reagent and method for repairing fbn1t7498c mutation using base editing
WO2019086007A1 (en) Sgrna for targeting and guiding cas9 protein to efficiently cleave tcr and b2m gene loci
CN106967716A (en) Double gRNA, double gRNA libraries, double gRNA vector libraries and its preparation method and application
CN106755089B (en) Cell line for expressing goat lymphocyte activating molecules and construction method and application thereof
CN108148866B (en) HCBP6 gene knockout cell line and construction method thereof
CN109706148A (en) A kind of gRNA, gRNA composition and electric shifting method for knocking out BCL11A gene or BCL11A genetic enhancer
CN101918578A (en) Promoter detection and analysis
CN106544360B (en) A method of terminating the transcription of lncRNA diallele
CN104789597B (en) A kind of vitro construction method of silkworm cytoplasmic polyhedrosis virus
CN110747230A (en) Method for promoting bovine skeletal muscle satellite cell myogenic differentiation
CN114107299B (en) sgRNA for targeted knockout of duck cGAS gene and application thereof
CN110229816B (en) Construction method and application of sgRNA (ribonucleic acid) for knocking out RBP4 gene and RBP4 gene deletion cell strain
CN112226460B (en) Screening and breeding method of cell line for stably expressing porcine host restriction factor A3Z2 molecule and application thereof
CN114891786B (en) Dog Rosa26 gene and application thereof
CN105462986B (en) Pig specificity close friend site Pifs302 and its application
CN106177906A (en) The application of Ddb1 albumen
CN106565830A (en) Construction of Newcastle disease virus HN protein 119-site amino acid mutant
CN106075396A (en) The application of Cul4 albumen

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB03 Change of inventor or designer information

Inventor after: Wang Qing

Inventor after: Wang Fei

Inventor after: Guo Tao

Inventor after: Li Ruobi

Inventor after: Jiang Hongmei

Inventor after: Wang Ting

Inventor after: Zeng Ni

Inventor before: Wang Qing

Inventor before: Wang Fei

Inventor before: Guo Tao

Inventor before: Li Ruobi

Inventor before: Wang Hongmei

Inventor before: Wang Ting

Inventor before: Zeng Ni

CB03 Change of inventor or designer information
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant